While METTL3 and FTO have opposing roles in the regulation of m6A modification, it's noteworthy that due to differences in the signaling pathways involved, genetic knockdown of either of these genes enhances the sensitivity of BC cells to doxorubicin. The gene discussed is METTL3; the disease is breast cancer.